|
Euroz Hartleys June Quarter Update; FSGS Phase 3 FundedOpens in new window
|
30/07/2026 |
|
Euroz Hartleys Research Update: DXB | Building A Multi-Asset BiotechOpens in new window
|
22/07/2026 |
|
Euroz Hartleys Research Update: $10m Funding Secured; Phase 2-Ready Asset Acquired for Acute Kidney InjuryOpens in new window
|
17/07/2026 |
|
Euroz Hartleys Research Update: A$481 Million China Deal ExecutedOpens in new window
|
16/06/2026 |
|
Euroz Hartleys March Quarter Update; Terms Received for $70m Non-Dilutive FundingOpens in new window
|
30/04/2026 |
|
Euroz Hartleys Research Update: "Trial Well-Powered; Traditional Approval Pathway Selected”Opens in new window
|
28/04/2026 |
|
Pitt Street Research Update: A pivotal time is aheadOpens in new window
|
21/04/2026 |
|
Euroz Hartleys Sector Update: FDA Approves First Ever Drug to Reduce Proteinuria in FSGSOpens in new window
|
14/04/2026 |
|
Euroz Hartleys Research UpdateOpens in new window
|
07/04/2026 |
|
Euroz Hartleys Research | DXB | Phase 3 Trial Fully RecruitedOpens in new window
|
15/12/2025 |
|
Orphan drug payday coming soonOpens in new window
|
01/12/2025 |
|
Potential Upcoming Catalysts and TimingOpens in new window
|
09/11/2025 |
|
Key Opinion Leader (KOL) InterviewOpens in new window
|
27/10/2025 |
|
September Quarter UpdateOpens in new window
|
29/10/2025 |
|
PARASOL Analysis Supports Accelerated Approval Pathway; FDA Feedback NextOpens in new window
|
08/10/2025 |
|
FDA Confirms Proteinuria for Full Approval, Increasing Likelihood of USA Deal?Opens in new window
|
28/04/2025 |
|
Euroz Hartley Analyst Coverage April 2024Opens in new window
|
30/04/2024 |